Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial

BACKGROUND: The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled epirubicin/cyclophosphamide followed by paclitaxel (EC→T) (every 3 w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Moebus, Volker, Jackisch, Christian, Schneeweiss, Andreas, Huober, Jens, Lueck, Hans-Joachim, du Bois, Andreas, Thomssen, Christoph, Kurbacher, Christian, Kuhn, Walther, Nitz, Ulrike, Runnebaum, Ingo B., Hinke, Axel, Kreienberg, Rolf, Untch, Michael
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3714019/
https://ncbi.nlm.nih.gov/pubmed/23860204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt145
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars